Thyrocare Promoter Sells 9.9% Stake for Rs 986 Crore

In a significant transaction, Docon Technologies, a key promoter of Thyrocare Technologies Ltd, has divested a 9.9% stake in the diagnostic chain. This sale, conducted via multiple bulk and block deals on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE), amounted to Rs 986 crore.

Details of the Transaction

The stake sale involved 1,57,69,696 equity shares. Of these, over 1.31 crore shares were offloaded through block deals, while 10 lakh shares were sold via bulk deals on the NSE. An additional 16.01 lakh shares were transacted through a bulk deal on the BSE. The shares were priced between Rs 624 and Rs 631.71 each, culminating in a total transaction value of Rs 985.86 crore.

Impact on Docon's Holdings

Following the sale, Docon Technologies' stake in Thyrocare has decreased from 60.92% to 51.02%. This marks a continuation of Docon's strategy, as the company had previously sold a 10% stake in Thyrocare for Rs 667 crore in October of the previous year.

Institutional Buyers and Market Reaction

The stake sale witnessed participation from a diverse group of institutional investors, including HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Insurance giants Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance were also involved, alongside global players like Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority.

In response to the transaction, Thyrocare Technologies' stock saw a rise, gaining nearly 3% to close at Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE.

The sale underscores the dynamic nature of shareholder structures in major corporations and reflects a broader trend of promoters strategically divesting stakes to optimize business operations and investor relations.